WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal — Warptech Lab News

Storia in 16 fonti

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

Raccontata da

handelsblatt.com

thehindubusinessline.com

independent.co.uk

hindustantimes.com

ilsole24ore.com

barrons.com+4 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

barrons.comStai leggendo1 mese fa

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

Timeline cronologica

martedì 9 giugno 2026·cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
martedì 9 giugno 2026·lecho.be
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…

1 mese fa

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.

Leggi questa versione → originale

hindustantimes.com1 mese fa

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News

Leggi questa versione → originale

economictimes.indiatimes.com1 mese fa

$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent

British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in cancer treatments. The acquisition significantly strengthens GSK's focus on…

Leggi questa versione → originale

cityam.com1 mese fa

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

Leggi questa versione → originale

statnews.com1 mese fa

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

Leggi questa versione → originale

martedì 9 giugno 2026·

handelsblatt.com

Nuvalent: GSK übernimmt Krebsspezialisten für 10,6 Milliarden Dollar

Der britische Pharmariese will mit der Übernahme des US-Biotechs sein Onkologie-Portfolio ausbauen. Es wäre ein früher Erfolg des neuen Konzernchefs Miels.

martedì 9 giugno 2026·

thehindubusinessline.com

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion

GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.

martedì 9 giugno 2026·

cityam.com

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

martedì 9 giugno 2026·

endpoints.news

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

martedì 9 giugno 2026·

statnews.com

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

martedì 9 giugno 2026·

independent.co.uk

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

martedì 9 giugno 2026·

lecho.be

GSK rachète Nuvalent pour plus de 10 milliards de dollars

GSK va racheter l'américain Nuvalent pour 10,6 milliards de dollars. L’opération, qui devrait être officialisée au troisième trimestre, offre une prime de 40% par rapport aux près…

martedì 9 giugno 2026·

hindustantimes.com

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News

martedì 9 giugno 2026·

ilsole24ore.com

Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent

Operazione da 10,6 mld di dollari con il lancio di un'Opa

martedì 9 giugno 2026·

benzinga.com

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.

martedì 9 giugno 2026·

barrons.com

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

martedì 9 giugno 2026·

benzinga.com

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.

martedì 9 giugno 2026·

newsbytesapp.com

GSK buys US biopharma company Nuvalent for $10.6B

Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.

martedì 9 giugno 2026·

malaymail.com

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

martedì 9 giugno 2026·

statnews.com

Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more

GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology

martedì 9 giugno 2026·

milanofinanza.it

Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…

L’intesa prevede il lancio di un’offerta pubblica di acquisto su tutte le azioni in circolazione della società americana al prezzo di 124 dollari per azione in contanti

martedì 9 giugno 2026·

statnews.com

Gilead and Merck's latest trial success and flop

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com